SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

TLRY is trending following reports that Trump is considering reclassifying marijuana, a move seen as a major catalyst for the cannabis industry. The community is buzzing about potential rallies and short squeezes, with many anticipating significant gains. Discussions also include the potential impact on other cannabis stocks and the broader implications for the sector.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending amid discussions of its recent earnings report and future AI guidance, with the community parsing mixed signals. Despite strong revenue and AI growth, some investors are concerned about margin pressures and the lack of specific long-term forecasts. Analyst upgrades are countered by community members pointing to potential overvaluation and sector rotation.

Jiuzi Holdings, Inc. engages in franchise and operation of retail stores. The firm sells new energy vehicles (NEVs) under the brand name Jiuzi. It operates through the NEVs Sales and Franchise Services segments. The company was founded on October 10, 2019 and is headquartered in Hangzhou, China.

Jiuzi Holdings Inc

Jiuzi Holdings is trending due to news surrounding a significant commitment to expand its private placement to $1 billion, sparking discussion about potential for high gains. However, the community is also wary, with some users labeling the stock a "scam" and expressing concerns about Chinese stocks in general and potential dilution. Some traders are looking at similar stocks, hoping for a related sympathy run.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending due to community discussion around its cancer treatment pipeline, particularly after positive data in prostate cancer trials, leading to speculation about potential partnerships or a buyout. Investors believe the company is undervalued, with a high short interest creating potential for a short squeeze. The community is focused on the upcoming catalysts and continued data releases.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst ($BCRX) is trending as traders discuss the potential impact of the upcoming FDA decision on Orladeyo for pediatric patients, with some anticipating a revenue boost while others believe it's already priced in. Community members are actively debating the stock's valuation, short interest, and the potential for a buyback program to drive the price higher. The acquisition of Astria Therapeutics and the departure of a board member are also being considered as factors influencing the stock's future performance.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi (FRMI) is trending due to a significant stock drop following news of losing its first major tenant for its Texas data center project, sparking discussions about the company's future viability and potential bankruptcy. While some investors believe the sell-off is an overreaction and a buying opportunity, others express concerns about the company's lack of revenue and permits, viewing it as a risky venture amid the AI infrastructure hype. Community sentiment is mixed, with some calling it a scam and others seeing long-term potential if Fermi can secure new tenants and funding.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon's stock is trending after a surprising announcement that CEO Calvin McDonald will step down, coupled with better-than-expected quarterly results. The community is actively discussing the potential implications of this leadership change, along with the company's growth strategy and the impact of tariffs on margins. Investors are also reacting positively to the approval of a $1 billion increase to the stock repurchase program.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community rallies around its positive ethos, encouraging each other with the phrase 'We're all gonna make it.' Discussions highlight the strong community, long-term vision, and the potential for significant gains within the Solana meme coin ecosystem. The focus remains on community building and a shared belief in the project's future success.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge to new highs, driven by a potential supply squeeze and growing industrial demand, particularly in green technologies and AI. The community is actively discussing the possibility of a sustained breakout, with some anticipating a gamma squeeze and a run to triple-digit prices, while others caution about overbought conditions and potential pullbacks. Discussions also include expectations around shifts in Fed policy and impacts on the dollar.

Katapult Holdings, Inc. is an e-commerce focused financial technology company. The firm is engaged in the provision of e-commerce point-of-sale lease-purchase options for nonprime U.S. consumers. It offers its customers a lease purchase transaction processing system with no long-term obligation and options for ownership. The company was founded in August 2019 and is headquartered in Plano, TX.

Katapult Holdings Inc

KPLT is trending amid discussions about a potential merger and its impact on shareholder value, as well as ongoing speculation around a possible short squeeze. Community members are actively debating the company's value after a proposed all-stock transaction and analyzing its potential for growth. The stock is also experiencing high volatility and unusual trading volume, prompting discussions about potential catalysts and market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stock Traders Purchase Large Volume of Call Options on Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the target of unusually large options trading on Monday. Traders bought 3,255 call options on the stock. This represents an increase...

Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen raised Milestone Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Sunday...

What is HC Wainwright's Estimate for MIST FY2025 Earnings?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Research analysts at HC Wainwright raised their FY2025 earnings estimates for shares of Milestone Pharmaceuticals in a note issued to...

Milestone Pharmaceuticals (NASDAQ:MIST) Announces Earnings Results, Beats Expectations By $0.05 EPS

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus...

Simplify Asset Management Inc. Purchases 140,000 Shares of Milestone Pharmaceuticals Inc. $MIST

Simplify Asset Management Inc. lifted its position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) by 16.5% in the 2nd quarter, according to its most recent Form 13F filing...

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty

Investing.com -- TD Securities downgraded Milestone Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for its lead drug, etripamil, following a Complete Response Letter from the U.S. Food and Drug Administration.The FDA issued a Complete Response Letter for MIST’s etripamil New Drug Application for paroxysmal supraventricular tachycardia (pSVT), citing chemistry, manufacturing, and controls issues. While no safety or efficacy concerns were raised, the agency requested additional data on nitrosamine impurities based on new draft guidance published in September 2024, months after MIST had resubmitted its New Drug Application . The FDA also flagged the need for an inspection at a third-party facility performing release testing, which changed ownership during the New Drug Application review.

Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/03/28/3051260/0/en/FDA-Issues-Complete-Response-Letter-for-Etripamil-for-PSVT.html">not approve</a> its lead investigational product, Cardamyst.The nasal spray is under development to treat episodes of abnormal heart rhythm associated with Paroxysmal supraventricular tachycardia (PSVT).The FDA highlighted two key Chemistry, Manufacturing and Controls (CMC) issues.The regulator asked the company to submit additional information on nitrosamine impurities based on the new draft guidance issued after the New Drug Application (NDA) submission. &nbsp;The agency also said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices.Milestone Pharmaceuticals CEO Joe Oliveto said that the company is “deeply disappointed” by the letter but remains committed to the potential of the drug in treating patients with PSVT.“Our team is evaluating the feedback provided and intends to request a Type A meeting to discuss the issues raised in the CRL,” Oliveto said. “We are appreciative of the FDA’s efforts and are confident we can collaborate with the agency with the goal of addressing these issues in a resubmission.”The FDA did not raise any concerns regarding the drug’s clinical safety or efficacy, the company said.The nasal spray has been designed as a self-administered rapid response therapy, thereby bypassing the need for immediate medical oversight, it explained.On Stocktwits, retail investor sentiment about Milestone Pharmaceuticals dropped slightly within the ‘extremely bullish’ territory (89/100), while message volume remained at ‘extremely high’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:652/152;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_28_at_12_10_06_PM_png_e7518f6d31.webp" alt="MIST's Sentiment Meter and Message Volume as of 12:10 p.m. ET on March 28, 2025 | Source: Stocktwits" width="652" height="152"><figcaption>MIST's Sentiment Meter and Message Volume as of 12:10 p.m. ET on March 28, 2025 | Source: Stocktwits</figcaption></figure>Following the company’s announcement, HC Wainwright kept a ‘Buy’ rating on Milestone pharmaceuticals and noted that the FDA flagged no concerns around the efficacy of the product, thereby reaffirming the integrity of the clinical data.However, the firm expects the product's launch to be delayed until the first half of 2026.<a href="https://stocktwits.com/symbol/MIST">Shares of Milestone Pharmaceuticals</a> fell over 55% this year and by over 45% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/hyperscale-data-shares-drop-despite-completing-first-nvidia-gpu-installation/chJ3iDORbEC">Hyperscale Data Stock Drops Despite Completing First Nvidia GPU Installation – But Retail Turns Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive 

The FDA said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices.

Equity

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

Milestone Pharmaceuticals Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Current Price	$2.95
Prev Close	$2.67
Open	$2.63
Dividend Yield	0.00%
50-Day Moving Average	$2.17
Beta	1.27
Avg. Volume	3.04M
PE Ratio	-3.42

52-Week High	$2.97
52-Week Low	$0.6254
Market Capitalization	$251.25M
EPS (Annual)	-$0.6674
Price to Book	12.26
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MIST
Milestone Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MIST News

MISTMilestone Pharmaceuticals Inc